Oncogenic KRAS impairs EGFR antibodies' efficiency by C/EBPβ-dependent suppression of EGFR expression.
Derer S, Berger S, Schlaeth M, Schneider-Merck T, Klausz K, Lohse S, Overdijk MB, Dechant M, Kellner C, Nagelmeier I, Scheel AH, Lammerts van Bueren JJ, van de Winkel JG, Parren PW, Peipp M, Valerius T.
Derer S, et al.
Neoplasia. 2012 Mar;14(3):190-205. doi: 10.1593/neo.111636.
Neoplasia. 2012.
PMID: 22496619
Free PMC article.